Row over drugs firm chief's pension

The departing boss of AstraZeneca will reportedly enjoy a "golden goodbye" worth up to £40 million despite leaving the pharmaceuticals giant with concerns over the development of new drugs.

Chief executive David Brennan last week announced he will step down in June after slashing full-year profits hopes and coming under fire for not acting sooner to tackle a shortage of blockbuster drugs as patents expire.